Risk Stratification of Patients with Prostate Cancer

At 25 weeks, FACT-P total score remained comparable between the arms.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

The PDUFA target action date has been set for August 29, 2025.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

The application is supported by data from the pivotal phase 3 ARANOTE trial.

Catch up on all the notable drug and device approvals in urology over the past year.